drugset / Trial / NCT04905121

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

NCT04905121

Phase 1 Terminated 4 enrolled Beckley Psytech Limited
NaSingle-groupOpen-labelTreatment

Summary

This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Timeline

Start
2021-08-11
Primary completion
2022-04-22
Completion
2022-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified Oral